As US FDA Commissioner Scott Gottlieb has touted the use of seamless clinical trial designs, the agency appears to promote the concept in a new draft guidance on developing drugs for the treatment of noncirrhotic nonalcoholic steatohepatitis (NASH) with liver fibrosis.
In the guidance published Dec. 3 that otherwise contains mostly expected information, the agency says that, "Sponsors could use...